Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry

ConclusionIn the present setting (specialized headache care in Germany), 13.1% of the patients had failed  ≥ 2 triptans. Triptan failure was associated with increased migraine severity and disability, emphasizing the importance of establishing an effective and tolerable acute migraine medication. Acute treatment optimization might include switching to one of the triptans with the highest responder rates and/or to a different acute medication class.Trial registrationThe DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081).
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research